Three University of Pittsburgh spinout biotech companies have been on a roll, starting clinical trials, winning federal grants and raising investment capital.
Squirrel Hill-based Ocugenix Corp. has begun a Phase 1 clinical trial for Ocu-110, a small molecule drug to treat wet macular degeneration, an eye disease that can cause severe and rapid vision loss. The testing phase, based on research licensed from Pitt in 2017, is expected to be done by late summer 2024.
Some 200,000 new cases of the disease are diagnosed annually and CEO Sean McDonald estimated the size of the therapy market at $13 billion.
“These are blockbuster drug categories by any measure,” Mr. McDonald said. “It’s an exciting time.”
Ocu-110 has never been used to treat any ailment. In addition to wet macular degeneration, the drug will be used to treat patients with proliferative diabetic retinopathy, also marked by the abnormal growth of blood vessels in the eye.
Phase 1 clinical trials are done in small groups of patients to determine safety and side effects.
Ocugenix, a pre-revenue company, was founded in 2015 and employs 10 people. Ocu-110 was designed to limit the excessive growth of fibrosis and blood vessels in the eye.
Ocugenix has raised $10 million from investors. No dose-related safety issues were found in animal studies of the drug, Mr. McDonald said.
A second Pitt spinout company, Duo Oncology Inc., which has offices in Hazelwood Green, has received a one-year $380,000 Small Business Technology Transfer grant from the National Cancer Institute to test the safety and efficacy of DUO-307, the company’s second medicine. The drug, a nano-medicine, uses particles that are 10 times smaller than the ones currently used in cancer medications, founder and CEO Sam Rothstein said, making it easier for the drug to penetrate dense tumor tissue.
The drug will be used to treat pancreatic and liver cancers, which have low rates of survival.
Clinical trials were expected to begin within six months in Australia for the company’s first product, DUO-207, which will be tested in patients with bile duct, ovarian and other cancers, Mr. Rothstein said.
The company, which was started in 2021 and employs two full-time people and a number of contracted scientists, has raised $4 million from private investors, but has not yet generated revenue.
DUO-307 is a combination nanomedicine that kills tumor cells and stimulates anti-tumor immune activity. The smaller size of the drug molecules allows more efficient delivery of medicine to the target site while sparing healthy tissue.
“We see ultra small nanomedicines as an innovative approach to more effectively deliver new chemical entities and novel drug combinations to tumor tissue with the goal of stimulating anti-tumor immunity to recognize and destroy the tumor,” Song Li, director of the Center for Pharmacogenetics at Pitt and Duo Oncology co-founder, said in a prepared statement.
Lastly, Squirrel Hill-based LyGenesis Inc. announced that it raised more than $19 million in a Series A-2 financing round led by Prime Movers Lab, of Jackson, Wyo., with follow-on funding from Juvenescence, a biotech company based in Ireland. The money will allow LyGenesis to complete Phase 2a clinical trial and advance other cell therapies.
“LyGenesis’ regenerative cell therapies have the potential to transform the lives of patients who are either medically ineligible for an organ transplant or are awaiting an organ to become available,” biologist and Prime Movers Lab partner Justin Briggs said in a prepared statement. “Using lymph nodes as bioreactors to grow ectopic organs is the type of platform technology that could revolutionize the treatment of multiple diseases and beneficially affect millions of lives.”
Mr. Briggs will be taking a seat on the LyGenesis board.
In April, LyGenesis inked a research agreement with Uptown-based Imagine Pharma to find new treatments for Type 1 diabetes. In October, Imagine Pharma announced raising $32.8 million in investments, bringing the total investment in the startup to $40 million.
LyGenesis and other biotech startups may be riding a bigger wave in how venture capital is invested.
Annual venture capital funding for life science companies overall was returning to pre-pandemic levels in 2023 since peaking at $33 billion in 2021, according to Dallas-based commercial real estate and advisory services firm CBRE Group Inc. While the biggest share of venture capital was distributed in Series B or mid-stage rounds 20 years ago, funding has more recently targeted early startups.
Kris B. Mamula: kmamula@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.